Valarcher, Jean, Hägglund, Sara, Näslund, Katarina, Jouneau, Luc, Malmström, Ester, Boulesteix, Olivier, Pinard, Anne, Leguéré, Dany, Deslis, Alain, Gauthier, David, Dubuquoy, Catherine, Pietralunga, Vincent, Remot, Aude, Falk, Alexander, Shevchenko, Ganna, Bergström Lind, Sara, Von Brömssen, Claudia, Vargmar, Karin, Zhang, Baoshan, Kwong, Peter, Rodriguez, María Jose, Garcia Duran, Marga, Schwartz-Cornil, Isabelle, Taylor, Geraldine, Riffault, Sabine, Department of Clinical Sciences, Swedish University of Agricultural Sciences (SLU), Virologie et Immunologie Moléculaires (VIM (UR 0892)), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Plateforme d'Infectiologie Expérimentale (PFIE), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Infectiologie et Santé Publique (UMR ISP), Université de Tours-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Department of Chemistry [Uppsala, Sueden], Biomedical Center = Biomedicinskt centrum [Uppsala, Sueden] (BMC), Uppsala University-Uppsala University, Department of Energy and Technology, Department of Biomedicine and Veterinary Public Health, Vaccine Research Center (VRC), National Institutes of Health [Bethesda] (NIH), INGENASA, Institute for Animal Health, the Pirbright Institute, Swedish Foundation of Strategic Research (SB16-0039), Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) (USA), European Project: 633184,H2020,H2020-SFS-2014-2,SAPHIR(2015), Université de Tours (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), The Pirbright Institute, and Biotechnology and Biological Sciences Research Council (BBSRC)
The induction of long-lasting clinical and virological protection is needed for a successful vaccination program against the bovine respiratory syncytial virus (BRSV). In this study, calves with BRSV-specific maternally derived antibodies were vaccinated once, either with (i) a BRSV pre-fusion protein (PreF) and MontanideTM ISA61 VG (ISA61, n = 6), (ii) BRSV lacking the SH gene (ΔSHrBRSV, n = 6), (iii) a commercial vaccine (CV, n = 6), or were injected with ISA61 alone (n = 6). All calves were challenged with BRSV 92 days later and were euthanized 13 days post-infection. Based on clinical, pathological, and proteomic data, all vaccines appeared safe. Compared to the controls, PreF induced the most significant clinical and virological protection post-challenge, followed by ΔSHrBRSV and CV, whereas the protection of PreF-vaccinated calves was correlated with BRSV-specific serum immunoglobulin (Ig)G antibody responses 84 days post-vaccination, and the IgG antibody titers of ΔSHrBRSV- and CV-vaccinated calves did not differ from the controls on this day. Nevertheless, strong anamnestic BRSV- and PreF-specific IgG responses occurred in calves vaccinated with either of the vaccines, following a BRSV challenge. In conclusion, PreF and ΔSHrBRSV are two efficient one-shot candidate vaccines. By inducing a protection for at least three months, they could potentially improve the control of BRSV in calves.